Reponse to Questions Raised Over Canadian Oversight Of Clinical Trials
I read, with great interest, the article published this Tuesday (09/16/14) in the Toronto Star on Drug-testing rules broken by…
Oncology drug reimbursement climate in Canada
Canada remains a prime destination for the expansion of both early and late phase oncology clinical trials due the fact…
Reverse Feasibility in Action – Transcript of interview with Dr. Quincy Chu
In this interview, Dr. Quincy Chu, Medical Oncologist at the Cross Cancer Institute in Edmonton Alberta, discusses the ways in…
Value of Canadian oncology centers for early phase trials – Transcript of interview with Dr. Stephen Welch
Given the increased focus on speed of activation for oncology studies, sponsors are under pressure to select top-performing investigative sites…
Tips on developing oncology biomarkers and companion diagnostics – Transcript of interview with Dr. John Reddington
The increased demand for targeted therapeutics has prompted oncology drug developers to uncover innovative solutions to new challenges. Fueled by…
How to get the most out of data warehousing and analytics – Transcript of interview with Steve Sweeney
With the volume of medical data doubling every 5 years, the challenge has now become how to derive actionable insights…
How to double your oncology enrolment targets
Back in June of 2011, a leading U.S. biotech company, currently developing multiple therapeutic candidates, was planning a Phase I/II…
How to speed up site start-up by 50%: Part 2 – Contract Negotiation
Like patient consent forms, site Clinical Trial Agreements (CTA) have become increasingly complex, making their review a major roadblock to…